Transitioning from stealth to commercial impact requires both capital and platform validation. Alexandros Pantalis, CEO of Phagos reflects on raising €25M Series A and the regulatory milestones that enabled first commercial sales of personalised phage-based veterinary medicines in France.
Session Topics:
Livestock
Nutrition
Antimicrobial Resistance
Phage
Funding
Disease
Speaker(s):
Alexandros Pantalis
Founder and CEO
Phagos
Time:
4:25pm - 4:45pm
Agenda Track No.:
Track 3
Summary:
Session Will be Recorded - Attend live or Watch On-Demand
Session Type:
General Session (Presentation)
Force Inline Description:
0